Ignite Creation Date:
2024-07-17 @ 11:04 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06481839
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-07-01
First Post:
2024-06-24
Brief Title:
Impact of Starting Dose of Vasopressor on Hemodynamic Response in Shock
Sponsor:
University of Illinois at Chicago
Organization:
University of Illinois at Chicago
Study Overview
Official Title:
Impact of Starting Dose of Vasopressor on Hemodynamic Response in Shock
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is designed to assess the effect of initial vasopressor dose on clinical outcomes To date there are no clinical guidelines or recommendations regarding the dose of vasopressor medication that should be initiated before titrating to a mean arterial pressure MAP in patients with circulatory shock High heterogeneity and clinical equipoise regarding this variable exist in routine clinical practice However there is strong evidence that delays in achieving MAP goals lead to worse clinical outcomes The study will randomize patients with circulatory shock to a low 5mcgmin of norepinephrine or high 15mcgmin of norepinephrine initial starting dose followed by the usual protocolized titration to MAP goal The time to reach the goal MAP organ dysfunction hospital length of stay and mortality will be measured for each group
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None